Outset Medical (OM) Q1 2026 earnings review
Margins Soar While Top-Line Stalls on Capital Lumpiness
Outset Medical's Q1 delivered a mixed bag: revenue fell 6% YoY to $27.9M due to delayed capital orders, but gross margins expanded massively by over 600 bps to 43.4%. The persistent 'lumpiness' in console sales continues to plague top-line predictability, a concerning trend carried over from FY25. However, the bottom-line execution is undeniable. Total cash burn came in better than expected ($12M), prompting management to lower its full-year cash use guidance. The path to profitability looks credible with a $161M cash runway, but reaffirming the $125-$130M revenue guidance sets up a high-stakes, back-half-weighted year reliant on the successful launch of the next-generation Tablo system.
🐂 Bull Case
Product gross margin hit a record 52.4%, and service margins expanded to 25.5%. The fundamental profitability profile of the Tablo console is strengthening significantly.
Using only $12M in cash during Q1 allows management to improve full-year burn guidance to under $40M. The $161M balance sheet appears sufficient to bridge the gap to cash flow breakeven without dilutive raises.
🐻 Bear Case
Product revenue declined 13% YoY due to deal 'lumpiness'. A persistent inability to forecast exact closure dates for large health system deals creates ongoing quarter-to-quarter execution risk.
Despite a growing installed base, recurring revenue (consumables + service) was $22.5M, slightly down from $22.7M a year ago. If utilization is strong, this metric should be compounding, not stalling.
⚖️ Verdict: ⚪
Neutral. The operational discipline and margin expansion are highly impressive, securing the balance sheet. However, a growth company fundamentally needs to grow. Reliance on a steep H2 revenue ramp leaves no margin for error.
Key Themes
Capital Order 'Lumpiness' Plagues the Top Line
Total product revenue fell 13% YoY to $18.6M. Management attributed this to the 'lumpiness' of capital sales, noting ~$1M in deals slipped out of Q1. While pipeline depth remains theoretically strong, the long enterprise sales cycle continues to create forecasting misses. The recent addition of a new commercial leader, Derek Elliott, is tasked with tightening this exact issue, but the company must prove it can actually close these large deals predictably.
Gross Margin Expansion is Real and Accelerating
The strongest data point of the quarter: Total gross margin expanded over 600 bps YoY to 43.4%. Both segments hit record highs: Product gross margin reached 52.4% (up from 48.3% YoY), and Service/Other hit 25.5% (up from 9.2% YoY). This proves that the cost-down initiatives and operating leverage are taking hold as the installed base matures.
Next-Generation Tablo & Cybersecurity Positioning
Management expects the next-generation Tablo—the first dialysis system cleared under the FDA's strict 2025 cybersecurity requirements—to launch fully by Q3. Amid rising hospital cyberattacks, framing Tablo's 'Secure by Design' architecture as a differentiator could unlock stalled IDN capital budgets and stimulate a refresh cycle among older legacy fleets.
Recurring Revenue Growth Has Stalled
Recurring revenue (consumables and service) was $22.5M in Q1, effectively flat against $22.7M in the prior-year period. Management indicated consumable sales were slightly stronger than expected, yet the overall flat YoY growth contradicts the narrative of a compounding installed base with high utilization. This specific metric must re-accelerate to support the 'razor-and-blade' valuation model.
Enterprise Insourcing Implementations
The company continues to prove its ability to execute massive implementations, replacing outsourced dialysis providers. Management cited a recent two-day go-live at a 400-bed Texas health system, supported by Outset's clinical teams. This turnkey implementation service acts as a significant moat, easing the change-management friction that typically scares off hospital CNOs.
Steep Back-Half Execution Required
By maintaining full-year revenue guidance of $125M-$130M after a $27.9M Q1, Outset is implying it will need to average ~$33M-$34M per quarter for the rest of the year. Management explicitly stated growth will be back-loaded in Q3 and Q4. This creates a high-wire act for the second half of FY26.
Other KPIs
Cash management is accelerating favorably. The company used only $12M in Q1, outperforming internal forecasts due to working capital optimization. With a lowered FY26 cash use target of <$40M, the current balance sheet provides a multi-year runway, effectively removing immediate dilution risks.
Accelerating slightly. Up 6% from $27.5M in Q1 2025. Driven primarily by investments in systems and people, specifically higher general & administrative costs ($10.1M vs $8.3M). Despite the top-line stall, they are spending to support the upcoming next-gen launch.
Improving trend. The net loss narrowed from -$25.8M in the prior-year period, primarily driven by the massive expansion in gross profit dollars ($12.1M vs $11.1M) despite lower overall revenue.
Guidance
Stable/Maintained. Implies a 5% to 9% YoY growth against FY25's $119.5M. Because Q1 came in at -6% YoY, this guidance implies a significant acceleration is required in Q2-Q4. Management explicitly noted Q2 will see a 'modest step up' with the bulk of the growth arriving in Q3 and Q4.
Stable. The company is already executing at the higher end of this range (43.8% non-GAAP in Q1). Management noted that higher console mixes pull the margin to the lower end, while higher consumable mixes push it up. This target looks highly achievable based on Q1 performance.
Accelerating improvement. The company improved this outlook from a prior estimate of <$50M (a 15% improvement). Achieving this would be another step down from the $46.3M used in FY25, cementing the path to cash flow breakeven.
Key Questions
Recurring Revenue Disconnect
With an expanding installed base and claims of high utilization, why was recurring revenue flat YoY at $22.5M? Are there still lingering issues with customer inventory destocking or ordering patterns from FY25?
Capital Deal Slipped vs Lost
You noted roughly $1M in capital deals shifted out of Q1. Are these deals contractually signed and just awaiting site-readiness, or are they still in the verbal commitment phase subject to IDN budget changes?
Next-Gen Tablo Margins & Pricing
As the next-generation Tablo rolls out in Q2/Q3, what is the anticipated ASP impact, and will the transition temporarily compress product gross margins as you clear out legacy inventory?
Derek Elliott's 90-Day Plan
With a new commercial leader in place, what specific process changes are being implemented to solve the chronic forecasting and 'lumpiness' issues in the enterprise capital pipeline?